Immunomodulatory and anti-tumor activities of native and heat denatured Abrus agglutinin

被引:25
作者
Ghosh, Dipanjan [1 ]
Maiti, Tapas K. [1 ]
机构
[1] Indian Inst Technol, Dept Biotechnol, Kharagpur 721302, W Bengal, India
关键词
abrus agglutinin; lectin; heat denatured; Dalton's lymphoma; immunomodulator; immunoadjuvant; anti-tumor;
D O I
10.1016/j.imbio.2007.03.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Abrus agglutinin (AAG), a hetero tetrameric gal beta(1-3) NAc gal specific lectin, is isolated from seeds of Abrus precatorius. In our previous studies we found that the protein could act as an immunomodulator and immunoadjuvant in native (NA) and heat denatured (HDA) conditions. An anticancer effect of the lectin is reported, but its mode of action is not clearly known. In the present study, the anti-tumor activity of AAG (NA, HDA) has been evaluated in a murine Dalton's lymphoma (DL) ascites tumorogenic model. We found that treatment with both NA and HDA were able to decrease the tumor cell number in vivo and significantly increased median survival time. In vitro studies showed that AAG (NA, HDA) treatment of Dalton's lymphoma ascites cells (DLAC) resulted in growth inhibition at the concentration of 1 mu g/ml and above. Whereas, AAG (NA, HDA) at much lower concentrations (similar to 1 ng/ml) can stimulate peritoneal macrophage and spleen derived NK cells in vitro demonstrating cytotoxicity against DLAC. Cell cycle analysis showed an increased number of cells in Sub-G(0)/G(1) phase for in vitro and in vivo treatments. In summary, AAG (NA, HDA) at non-toxic concentration was able to elicit anti-tumor effects in DL bearing mice by stimulating the innate immune system and Th1 type immunomodulation. (c) 2007 Elsevier GmbH. All rights reserved.
引用
收藏
页码:589 / 599
页数:11
相关论文
共 36 条
[1]  
Beuth J., 1997, ANTI CANC DRUGS, V8, P53
[2]   The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies [J].
Bingle, L ;
Brown, NJ ;
Lewis, CE .
JOURNAL OF PATHOLOGY, 2002, 196 (03) :254-265
[3]   Immunology and immunotherapy of human cancer: present concepts and clinical developments [J].
Bremers, AJA ;
Parmiani, G .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 34 (01) :1-25
[4]  
DAS S, 1995, EXPERT OPIN INV DRUG, V4, P1293
[5]   Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy [J].
Dredge, K ;
Marriott, JB ;
Todryk, SM ;
Dalgleish, AG .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (10) :521-531
[6]   Probing the cons and pros of lectin-induced immunomodulation: Case studies for the mistletoe lectin and galectin-1 [J].
Gabius, HJ .
BIOCHIMIE, 2001, 83 (07) :659-666
[7]   PLANT-LECTINS AS INHIBITORS OF TUMOR-GROWTH AND MODULATORS OF HOST IMMUNE-RESPONSE [J].
GANGULY, C ;
DAS, S .
CHEMOTHERAPY, 1994, 40 (04) :272-278
[8]  
GANGULY C, 1991, IND J CANC CHEMOTHER, V13, P41
[9]   Immunodeficiency and cancer: prospects for correction [J].
Hadden, JW .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2003, 3 (08) :1061-1071
[10]   Oncopharmacological perspectives of a plant lectin (Viscum album agglutinin-I):: Overview of recent results from in vitro experiments and in vivo animal models, and their possible relevance for clinical applications [J].
Hajtó, T ;
Hostanska, K ;
Berki, T ;
Pálinkás, L ;
Boldizsár, F ;
Námeth, P .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2005, 2 (01) :59-67